Condition: Cerebral Venous Thrombosis · Sponsor: Kafrelsheikh University
Along with the current clinical trial, the efficacy and safety of a 20 mg rivaroxaban administered within 24 hours of randomization after having first-ever cerebral venous thrombosis compared to apixaban 5mg Bid were assessed through rate of recurrent VTE, mRS, rate of venous recanalization, HIT score, MoCA test, and central and peripheral heamoragic complications.
This description comes directly from the study's public registry record.
mohamed G. Zeinhom, MD · 2001009606828 · mohamed_gomaa@med.kfs.edu.eg
sherihan R. ahmed, MD · 2001113432342 · sherihan_rezq@med.kfs.edu.eg
Always discuss trial participation with your own doctor first.
| Kafr Elsheikh University Hospital | Kafr ash Shaykh, Egypt | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06531122